Table of Contents Author Guidelines Submit a Manuscript
Clinical and Developmental Immunology
Volume 2012 (2012), Article ID 370426, 9 pages
http://dx.doi.org/10.1155/2012/370426
Review Article

Familial Atypical Hemolytic Uremic Syndrome: A Review of Its Genetic and Clinical Aspects

1Interdepartmental PhD Program in Genetics, University of Iowa, Iowa City, IA52242, USA
2Division of Nephrology, Department of Internal Medicine, Carver College of Medicine, University of Iowa, 5270 CBRB, Iowa City, IA 52242, USA
3Laboratory of Molecular Genetics, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan 20122, Italy
4Center for HUS Control, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan 20122, Italy

Received 6 July 2012; Accepted 24 September 2012

Academic Editor: Michael A. Flierl

Copyright © 2012 Fengxiao Bu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [11 citations]

The following is the list of published articles that have cited the current article.

  • Lesley Rees, “Atypical HUS: time to take stock of current guidelines and outcome measures?,” Pediatric Nephrology, vol. 28, no. 5, pp. 675–677, 2013. View at Publisher · View at Google Scholar
  • Edward Zimbudzi, “Overcoming technical challenges when treating atypical hemolytic uremic syndrome with therapeutic plasma exchange,” International Journal of Nephrology and Renovascular Disease, vol. 6, pp. 245–248, 2013. View at Publisher · View at Google Scholar
  • Martin Christmann, Matthias Hansen, Carsten Bergmann, Dirk Schwabe, Joerg Brand, and Wilfried Schneider, “Eculizumab as First-Line Therapy for Atypical Hemolytic Uremic Syndrome,” Pediatrics, vol. 133, no. 6, pp. E1759–E1763, 2014. View at Publisher · View at Google Scholar
  • Larry A. Greenbaum, “Atypical Hemolytic Uremic Syndrome,” Advances in Pediatrics, 2014. View at Publisher · View at Google Scholar
  • Angela R. Melton-Celsa, “Shiga toxin (Stx) classification, structure, and function,” Microbiology Spectrum, vol. 2, no. 4, 2014. View at Publisher · View at Google Scholar
  • Olga Nikolajeva, Austen Worth, Rosie Hague, Nuria Martinez-Alier, Joanne Smart, Stuart Adams, E. Graham Davies, and H. Bobby Gaspar, “Adenosine Deaminase Deficient Severe Combined Immunodeficiency Presenting as Atypical Haemolytic Uraemic Syndrome,” Journal of Clinical Immunology, vol. 35, no. 4, pp. 366–372, 2015. View at Publisher · View at Google Scholar
  • Paula Vieira-Martins, Carine El Sissy, Pauline Bordereau, Aurelia Gruber, Jeremie Rosain, and Veronique Fremeaux-Bacchi, “Defining the genetics of thrombotic microangiopathies,” Transfusion and Apheresis Science, 2016. View at Publisher · View at Google Scholar
  • Alexander C. Wiseman, “Immunosuppressive Medications,” Clinical Journal Of The American Society Of Nephrology, vol. 11, no. 2, pp. 332–343, 2016. View at Publisher · View at Google Scholar
  • Julie Rayes, Lubka T. Roumenina, Marie Frimat, and Veronique Fremeaux-Bacchi, “Endothelial cells: source, barrier, and target of defensive mediators,” Immunological Reviews, vol. 274, no. 1, pp. 307–329, 2016. View at Publisher · View at Google Scholar
  • Joseph P Gaut, Sanjay Jain, John D Pfeifer, Katinka A Vigh-Conrad, Meagan Corliss, Mukesh K Sharma, Jonathan W Heusel, and Catherine E Cottrell, “Routine use of clinical exome-based next-generation sequencing for evaluation of patients with thrombotic microangiopathies,” Modern Pathology, 2017. View at Publisher · View at Google Scholar
  • K. Kottke-Marchant, “Diagnostic approach to microangiopathic hemolytic disorders,” International Journal of Laboratory Hematology, vol. 39, pp. 69–75, 2017. View at Publisher · View at Google Scholar